Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Finally Able To Move Firazyr Forward

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire reports positive phase III results for its HAE drug and may file a complete response in the next few months.

You may also be interested in...



Despite Rival's Supply Problems, No Guarantee That Shire Will Re-File Replagal In U.S.

Human Genetic Therapies division President Gregoire also says self-administration should be a key point of differentiation for Firazyr in the HAE market.

Despite Rival's Supply Problems, No Guarantee That Shire Will Re-File Replagal In U.S.

Human Genetic Therapies division President Gregoire also says self-administration should be a key point of differentiation for Firazyr in the HAE market.

Shire Says Vpriv Is A Viable Option for Cerezyme Patients; Gets PDUFA For Firazyr

Firazyr could enjoy a dosing advantage over other HAE drugs currently on the U.S. marketplace if it can get approval from FDA.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel